Cybin to Present Neuropsychiatry Pipeline at Jefferies Global Healthcare Conference
TL;DR
Cybin's presentation at Jefferies Global Healthcare Conference offers investors early insight into their Phase 3 neuropsychiatry pipeline with potential market advantages.
Cybin develops proprietary deuterated compounds like CYB003 for major depressive disorder and CYB004 for anxiety through clinical trials with FDA Breakthrough Therapy Designation.
Cybin's neuropsychiatry research aims to transform mental healthcare by developing effective treatments for depression and anxiety disorders worldwide.
Cybin is pioneering deuterated psychedelic compounds that could revolutionize how we treat mental health conditions through novel drug development approaches.
Found this article helpful?
Share it with your network and spread the knowledge!
Cybin Inc., a Phase 3 clinical-stage neuropsychiatry company, announced that Chief Business Officer George Tziras will present at the Jefferies Global Healthcare Conference scheduled for November 17-20, 2025, in London. The company, which trades on both the NYSE American and Cboe CA under the symbol CYBN, is developing proprietary drug discovery platforms and delivery systems aimed at transforming mental healthcare. The conference presentation comes as Cybin advances two key investigational compounds through clinical trials.
CYB003, the company's proprietary deuterated psilocin analog, is currently in Phase 3 studies for adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. This designation recognizes the drug's potential to demonstrate substantial improvement over existing therapies for serious conditions. Additionally, Cybin is developing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule currently in Phase 2 study for generalized anxiety disorder.
The company maintains a research pipeline of investigational compounds focused on 5-HT receptors, targeting the large unmet need for effective mental health treatments. Investors can access the latest news and updates relating to CYBN in the company's newsroom at https://ibn.fm/CYBN. Founded in 2019, Cybin operates across Canada, the United States, the United Kingdom, and Ireland, positioning itself as a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare.
The company's participation in the Jefferies conference reflects the growing institutional interest in novel psychiatric treatments and the expanding field of neuropsychiatry drug development. The full press release detailing Cybin's conference participation can be viewed at https://ibn.fm/bb3sl. The Jefferies Global Healthcare Conference brings together leading companies, investors, and analysts in the healthcare sector, providing a platform for companies like Cybin to showcase their clinical progress and strategic direction in addressing mental health conditions that affect millions worldwide.
Curated from InvestorBrandNetwork (IBN)
